Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma-Reference-Cited by-同舟云学术

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma

Published:2017-05-01 Issue:5 Volume:3 Page:620
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Shah Manish A.¹,Bang Yung-Jue²,Lordick Florian³,Alsina Maria⁴,Chen Meng⁵,Hack Stephen P.⁶,Bruey Jean Marie⁶,Smith Dustin⁶,McCaffery Ian⁶,Shames David S.⁶,Phan See⁶,Cunningham David⁷

Affiliation:

1. Department of Medicine, Weill Cornell Medical College, Center for Advanced Digestive Care, New York–Presbyterian Hospital, New York

2. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

3. University Cancer Center Leipzig, Leipzig, Germany

4. Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain5Vall d’Hebron Institute of Oncology, Barcelona, Spain

5. Biostatistics Department, Roche (China) Holdings Ltd, Shanghai, China

6. Genentech Inc, South San Francisco, California

7. Royal Marsden Hospital, London, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 247 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics;Targeted Oncology;2024-09-13

2. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group;Japanese Journal of Clinical Oncology;2024-08-24

3. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial;Gastric Cancer;2024-08-20

4. Advances in Personalized Oncology;Cancers;2024-08-16

5. Deciphering the FGFR2 Code: Innovative Targets in Gastric Cancer Therapy;Current Oncology;2024-07-29